Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder - Trial 2017-000211-16
Access comprehensive clinical trial information for 2017-000211-16 through Pure Global AI's free database. This phase not specified trial is sponsored by Eli Lilly and Company Limited and is currently status unknown. The study focuses on Major Depressive Disorder.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Eli Lilly and Company Limited
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
Have a serious or unstable medical illness, psychological condition, clinically significant laboratory or electrocardiogram (ECG) result, hypersensitivity to duloxetine, or to its inactive ingredients, frequent or severe allergic reactions to multiple medications, uncontrolled narrow-angle glaucoma, acute liver injury (for example, hepatitis) or severe cirrhosis (Child-Pugh Class C) that in the opinion of the investigator would compromise participation in the study or be likely to lead to hospitalization during the course of the study.
ICD-10 Classifications
Data Source
EU Clinical Trials Register
2017-000211-16
Non-Device Trial